Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Julie Feder as Chief Financial Officer. Ms. Feder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback